Details of the Drug

General Information of Drug (ID: DMQ7UL8)

Drug Name
Camostat
Synonyms
Camostat; 59721-28-7; camostate; Camostat [INN]; Camostatum [INN-Latin]; UNII-0FD207WKDU; CCRIS 7219; 4-(2-(2-(Dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate; 0FD207WKDU; C20H22N4O5; Camostat (INN); Foipan; FOY 305; FOY-305; Dimethylcarbamoylmethyl 4-(4-guqnidinobenzoyloxy)phenylacetat; foypan; Camostatum; CHEMBL85164; camostate-mesilate; [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate; p-Guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with N
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Phase 2 [1]
Affected Organisms
Humans
ATC Code
B02AB04: Camostat
B02AB: Proteinase inhibitors
B02A: ANTIFIBRINOLYTICS
B02: ANTIHEMORRHAGICS
B: BLOOD AND BLOOD FORMING ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 398.4
Logarithm of the Partition Coefficient (xlogp) 1.1
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 10,400 +/- 1,400 mcgmin/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 87.1 +/- 29.5 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 40 min [2]
Clearance
The clearance of drug is 4.5-7.3 mL/min/kg [3]
Elimination
Camostat mesylate is 89.8-95.6% eliminated in the urine and 1.0-1.7% eliminated in the feces [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.8 - 4.7 hours [3]
Metabolism
The drug is metabolized via the carboxyesterate to the active 4-(4-guanidinobenzoyloxy) phenylacetate [3]
Vd
The volume of distribution (Vd) of drug is 0.34-1.31 L/kg [3]
Chemical Identifiers
Formula
C20H22N4O5
IUPAC Name
[4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate
Canonical SMILES
CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
InChI
InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)
InChIKey
XASIMHXSUQUHLV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2536
ChEBI ID
CHEMBL590799
CAS Number
59721-28-7
UNII
0FD207WKDU
DrugBank ID
DB13729
TTD ID
D0Y6SQ
VARIDT ID
DR00883
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine protease unspecific (SP) TTEMV5X NOUNIPROTAC Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6432).
2 Ono Pharmaceutical: Foipan Camostat Mesilate Oral Tablets
3 Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration. Xenobiotica. 1994 Jan;24(1):79-92. doi: 10.3109/00498259409043223.
4 Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9.
5 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.